Literature DB >> 31455870

Specific diacylglycerols generated by hepatic lipogenesis stimulate the oncogenic androgen receptor activity in male hepatocytes.

Ya-Wen Cheng1, Kai-Wei Chen1, Han-Chun Kuo2, Ching-Hua Kuo2,3, Wei-Hsiang Lin4, Pei-Jer Chen1,4,5,6, Shiou-Hwei Yeh7,8.   

Abstract

BACKGROUND: Obesity-induced hepatocellular carcinoma (HCC) is more prevalent in males than in females, but the underlying mechanism remains unclear. The influence of hepatic androgen receptor (AR) pathway on the gender difference of HCC has been well documented. Here we investigated the role of hepatic lipogenesis, which is elevated in the livers of obese and nonalcoholic fatty liver disease (NAFLD) patients, in stimulating the AR pathway for the male preference of obesity induced HCC.
METHODS: Male C57BL/6J mice were fed a fructose-rich high carbohydrate diet (HCD) to induce hepatic lipogenesis. The effect of hepatic lipogenesis on AR was examined by the expression of hydrodynamically injected AR reporter and the endogenous AR target gene; the mechanism was delineated in hepatoma cell lines and validated in male mice.
RESULTS: The hepatic lipogenesis induced by a fructose-rich HCD enhanced the transcriptional activity of hepatic AR in male mice, which did not happen when fed a high fat diet. This AR activation was blocked by sh-RNAs or inhibitors targeting key enzymes in lipogenesis, either acetyl-CoA carboxylase subunit alpha (ACCα), or fatty acid synthase (FASN), in vivo and in vitro. Further mechanistic study identified that specific unsaturated fatty acid, the oleic acid (C18:1 n-9), incorporated DAGs produced by hepatic lipogenesis are the key molecules to enhance the AR activity, through activation of Akt kinase, and this novel mechanism is targeted by metformin.
CONCLUSIONS: Our study elucidates a novel mechanism underlying the higher risk of HCC in obese/NAFLD males, through specific DAGs enriched by hepatic lipogenesis to increase the transcriptional activity of hepatic AR, a confirmed risk factor for male HCC.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31455870     DOI: 10.1038/s41366-019-0431-z

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  40 in total

Review 1.  Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

Authors:  Asmaa-Ibrahim Gomaa; Shahid-A Khan; Mireille-B Toledano; Imam Waked; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

2.  Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.

Authors:  Judith Ertle; Alexander Dechêne; Jan-Peter Sowa; Volker Penndorf; Kerstin Herzer; Gernot Kaiser; Jörg F Schlaak; Guido Gerken; Wing-Kin Syn; Ali Canbay
Journal:  Int J Cancer       Date:  2011-03-14       Impact factor: 7.396

Review 3.  Prevalence, gender, ethnic variations, and prognosis of NASH.

Authors:  Etsuko Hashimoto; Katsutoshi Tokushige
Journal:  J Gastroenterol       Date:  2010-09-16       Impact factor: 7.527

4.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

Authors:  Christopher D Williams; Joel Stengel; Michael I Asike; Dawn M Torres; Janet Shaw; Maricela Contreras; Cristy L Landt; Stephen A Harrison
Journal:  Gastroenterology       Date:  2010-09-19       Impact factor: 22.682

5.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

6.  Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study.

Authors:  Yuichiro Eguchi; Hideyuki Hyogo; Masafumi Ono; Toshihiko Mizuta; Naofumi Ono; Kazuma Fujimoto; Kazuaki Chayama; Toshiji Saibara
Journal:  J Gastroenterol       Date:  2012-02-11       Impact factor: 7.527

Review 7.  Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.

Authors:  Elisa Fabbrini; Shelby Sullivan; Samuel Klein
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

8.  Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study.

Authors:  Jacob Alexander; Michael Torbenson; Tsung-Teh Wu; Matthew M Yeh
Journal:  J Gastroenterol Hepatol       Date:  2013-05       Impact factor: 4.029

Review 9.  NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Enrica Baldelli; Alessandra Marrazzo; Dante Romagnoli; Amedeo Lonardo
Journal:  Adv Ther       Date:  2017-05-19       Impact factor: 3.845

10.  Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies.

Authors:  S C Larsson; A Wolk
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.